We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,657

A defendant can get summary judgment without producing evidence
  • Foley & Lardner LLP
  • USA
  • August 24 2015

The Supreme Court explained in Celotex Corp. v. Catrett, 477 U.S. 317 (1986), that a party can obtain for summary judgment when its opponent has no


Amgen and Apotex do the biosimilar patent dance
  • Foley & Lardner LLP
  • USA
  • August 27 2015

Amgen has filed a complaint under the Biologics Price Competition and Innovation Act (BPCIA), asserting that a biosimilar application filed by Apotex


Delaware judges are finding patent claims indefinite post-Nautilus
  • Foley & Lardner LLP
  • USA
  • August 24 2015

It has been a little more than a year since the Supreme Court rendered its decision in Nautilus, lowering the standard for finding patent claim terms


Dr. Posner will see you now: 7th Circuit judges reignite a spirited debate over judicial internet research
  • Foley & Lardner LLP
  • USA
  • August 20 2015

The fat was really thrown into the fire in the Seventh Circuit yesterday on the long-mooted subject of the propriety of internet factual research by


Strip Club beats TCPA case with human intervention
  • Foley & Lardner LLP
  • USA
  • August 21 2015

The Sapphire Gentlemen’s Club in Las Vegas sends promotional text messages to its customers. Doing so involved multiple steps. First, a Club employee


SEC’s disclosure requirement on conflict minerals again ruled unconstitutional what now?
  • Foley & Lardner LLP
  • USA
  • August 19 2015

In a long-awaited decision, a three-judge panel of the U.S. Court of Appeals for the District of Columbia Circuit (DC Circuit) reaffirmed its prior


Protecting diagnostic innovation two actor infringement liability
  • Foley & Lardner LLP
  • USA
  • August 24 2015

In Akamai Techs. Inc. v. Limelight Networks, Inc., (August 13, 2015 Fed. Cir.) an en banc Federal Circuit unanimously held that direct infringement


A royalty by any other name: post-expiration payments after Kimble v. Marvel
  • Foley & Lardner LLP
  • USA
  • August 21 2015

Patent holders and accused infringers will need to continue being creative in drafting license agreements after the Supreme Court's recent decision


Kyle Bass loses round 1 of IPR attack against pharmabiotech patents
  • Foley & Lardner LLP
  • USA
  • August 26 2015

On August 24, 2015, the Patent Trial and Appeal Board (PTAB) declined institution of two petitions filed by Coalition For Affordable Drugs for Inter


Sanofi seeks IPR of Cabilly patent
  • Foley & Lardner LLP
  • USA
  • July 30 2015

On July 27, 2015, Sanofi-aventis U.S. LLC and Regeneron Pharmaceuticals, Inc. filed a petition for Inter Partes Review (IPR) of the “Cabilly II”